Carlsmed, Inc. (CARL)

Market Cap	243.46M
Revenue (ttm)	50.51M +85.9%
Net Income	-30.22M
EPS	-2.12
Shares Out	27.23M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,018
Open	8.83
Previous Close	8.83
Day's Range	8.66 - 8.91
52-Week Range	8.50 - 17.19
Beta	n/a
Analysts	Strong Buy
Price Target	19.25 (+115.32%)
Earnings Date	May 5, 2026

About CARL

Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.

• Industry: Health Information Services
• Sector: Healthcare
• IPO Date: Jul 23, 2025
• Employees: 127
• Stock Exchange: NASDAQ
• Ticker Symbol: CARL
• Website: https://carlsmed.com

Financial Performance

In 2025, Carlsmed's revenue was $50.51 million, an increase of 85.94% compared to the previous year's $27.17 million. Losses were -$30.22 million, 21.6% more than in 2024.

Analyst Summary

According to 4 analysts, the average rating for CARL stock is "Strong Buy." The 12-month stock price target is $19.25, which is an increase of 115.32% from the latest price.

Price Target

$19.25

(115.32% upside)

Analyst Consensus: Strong Buy